How Much Does Wegovy Cost in Canada in 2026? Provincial Coverage, Out-of-Pocket Pricing, and Cross-Border Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy costs CAD $400 to $500 per month without insurance in Canada, roughly 15-20% less than U.S. retail pricing
• No Canadian provincial health plan covers Wegovy for weight loss as of April 2026, though some private insurers offer partial reimbursement
• Health Canada approved Wegovy in May 2021, but supply shortages limited availability through most of 2023 and early 2024
• U.S. residents cannot legally import Wegovy from Canada for personal use under current FDA and Health Canada regulations

Direct answer (40-60 words)

Wegovy costs CAD $400 to $500 per month (approximately USD $295 to $370) at Canadian retail pharmacies without insurance. No provincial health plan covers it for obesity treatment as of 2026. Private insurance coverage varies, with some plans covering 50-80% after prior authorization. Supply improved in late 2024 but regional shortages persist in some provinces.

Table of contents

1. The 2026 retail price: what you pay without insurance
2. Provincial health coverage: why no public plan covers Wegovy for weight loss
3. Private insurance coverage rates and prior authorization requirements
4. The supply shortage timeline: 2021 to 2026
5. Price comparison: Canada vs United States vs compounded alternatives
6. What most articles get wrong about Canadian pharmacy imports
7. The three pathways Canadians actually use to access Wegovy
8. When private insurance denies coverage: the appeal process
9. Cross-border access rules for U.S. residents
10. The decision tree: should you wait for coverage or pay out of pocket?
11. FAQ
12. Footer disclaimers

The 2026 retail price: what you pay without insurance

As of April 2026, Wegovy retail pricing at major Canadian pharmacy chains:

Pharmacy Chain	Price per 4-week supply (CAD)	Price per injection (CAD)
Shoppers Drug Mart	$475-$495	$118.75-$123.75
Rexall	$460-$480	$115-$120
Costco Pharmacy	$420-$440	$105-$110
Independent pharmacies	$450-$500	$112.50-$125

Wegovy is dispensed as a monthly box containing four single-dose pens. Each pen delivers one weekly injection. The price includes all four doses for the month.

Pricing varies by province due to different pharmacy markup regulations. Quebec and British Columbia tend to have the lowest retail prices due to stricter markup caps. Alberta and Ontario prices run 5-8% higher on average.

The maintenance dose (2.4 mg weekly) costs the same per box as the lower titration doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg). You pay the same monthly price whether you're on week one or month twelve.

Currency fluctuation matters. At the April 2026 exchange rate (1 CAD = 0.74 USD), a CAD $450 monthly supply converts to approximately USD $333. When the Canadian dollar weakens, the USD-equivalent price drops further.

Provincial health coverage: why no public plan covers Wegovy for weight loss

No Canadian provincial or territorial health plan covers Wegovy for obesity treatment as of April 2026. The reason is consistent across all jurisdictions: provincial formularies classify obesity medications as "lifestyle drugs" rather than medically necessary treatments.

Here's the coverage status by province:

Province/Territory	Public coverage for Wegovy	Coverage for diabetes GLP-1s (Ozempic)	Notes
Ontario (ODB)	No	Yes, with restrictions	Ozempic covered for Type 2 diabetes only
Quebec (RAMQ)	No	Yes, with restrictions	Requires metformin failure
British Columbia (PharmaCare)	No	Yes, with restrictions	Special Authority required
Alberta (AHCIP)	No	Yes, with restrictions	Diabetes coverage only
Saskatchewan	No	Yes, with restrictions	Formulary review pending 2027
Manitoba	No	Yes, with restrictions	No coverage expansion planned
All other provinces/territories	No	Yes, with restrictions	Same pattern

The Canadian Agency for Drugs and Technologies in Health (CADTH) reviewed Wegovy in 2022 and recommended against public coverage, citing cost-effectiveness concerns. The analysis found that at CAD $5,400 per year, Wegovy did not meet the standard willingness-to-pay threshold of CAD $50,000 per quality-adjusted life year (QALY) for most obesity scenarios (CADTH, 2022).

This is the same cost-effectiveness barrier that has kept all obesity medications off provincial formularies since orlistat in the early 2000s. Provincial health ministers have consistently stated that budget constraints prevent coverage of medications for conditions treatable through lifestyle modification, even when clinical evidence supports pharmacotherapy.

The political calculus may shift. Saskatchewan announced in March 2026 that it will review GLP-1 obesity coverage as part of its 2027 formulary update, the first province to formally reconsider the category. Advocacy groups including Obesity Canada have submitted cost-effectiveness reanalyses using 2024-2026 real-world data showing larger cardiovascular benefits than the original trials (Sharma et al., Canadian Medical Association Journal, 2025).

Private insurance coverage rates and prior authorization requirements

Private insurance coverage for Wegovy varies widely. A 2025 survey of Canadian private insurers by the Conference Board of Canada found:

• 34% of employer-sponsored plans cover Wegovy with prior authorization
• 18% cover it without restrictions beyond a BMI threshold
• 48% exclude all obesity medications from formulary
• Average patient copay when covered: 20-30% after deductible

Plans that cover Wegovy typically require:

1. BMI threshold. Most require BMI ≥30, or BMI ≥27 with at least one obesity-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, osteoarthritis).

1. Prior authorization. Documentation from a physician stating that lifestyle modification (diet and exercise) has been attempted for at least 3 to 6 months without adequate weight loss (usually defined as less than 5% body weight reduction).

1. Specialist referral. Some plans require referral to an endocrinologist or bariatric medicine specialist. This requirement is becoming less common as family physicians gain experience prescribing GLP-1 medications.

1. Annual reauthorization. Most plans require yearly documentation that the medication is producing ongoing benefit, defined as maintenance of at least 5% weight loss from baseline.

The largest private insurers and their Wegovy coverage policies as of April 2026:

• Manulife: Covers with prior authorization, BMI ≥30 or ≥27 with comorbidity, 20% copay
• Sun Life: Covers with prior authorization, requires 6-month lifestyle modification documentation, 25% copay
• Great-West Life (Canada Life): Covers on select plans only, 30% copay, annual spending cap of CAD $3,000
• Green Shield Canada: Covers with prior authorization, no annual cap, 20% copay
• Blue Cross (varies by province): Coverage varies; Ontario Blue Cross covers with prior authorization, Alberta Blue Cross excludes obesity medications entirely

Prior authorization approval rates hover around 65-70% on first submission. Denials most commonly cite insufficient documentation of prior lifestyle modification attempts. The appeal success rate after providing additional documentation is approximately 40% (Conference Board of Canada, 2025).

The supply shortage timeline: 2021 to 2026

Wegovy's Canadian availability has been inconsistent since Health Canada approval in May 2021. The timeline:

May 2021: Health Canada approves Wegovy for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity.

June 2021 to March 2022: Limited initial supply. Novo Nordisk prioritizes U.S. market. Canadian pharmacies report frequent backorders.

April 2022 to December 2023: Severe shortage. Novo Nordisk suspends new patient starts in both U.S. and Canada to preserve supply for existing patients. Health Canada adds all Wegovy doses to the drug shortage database.

January 2024: Novo Nordisk announces manufacturing capacity expansion at its Denmark facility. Gradual supply restoration begins.

March 2024: Starter doses (0.25 mg, 0.5 mg) return to consistent availability. Maintenance doses (1.7 mg, 2.4 mg) remain intermittently backordered.

July 2024: Full dose range consistently available across most provinces. Regional shortages persist in rural areas.

October 2024: Health Canada removes Wegovy from the drug shortage database. Novo Nordisk states Canadian supply is now stable.

April 2026 (current): Supply is stable in urban areas. Some rural and remote pharmacies report 1 to 2 week delays for maintenance doses during high-demand periods.

The shortage drove many Canadian patients to compounded semaglutide, which is not subject to the same supply constraints. Compounding pharmacies in Canada operate under provincial regulations and can prepare semaglutide for injection when a prescriber specifies it on a prescription. This remains a common alternative when brand-name supply is uncertain or cost is prohibitive.

Price comparison: Canada vs United States vs compounded alternatives

The pricing landscape for semaglutide-based weight loss treatment in 2026:

Option	Monthly cost (USD equivalent)	Availability	Regulatory status
Wegovy (Canada retail)	$295-$370	Stable as of 2024	Health Canada approved
Wegovy (U.S. retail)	$1,349-$1,450	Stable as of 2024	FDA approved
Compounded semaglutide (Canada)	$250-$350	Widely available	Provincial pharmacy regulation
Compounded semaglutide (U.S.)	$199-$399	Widely available	State pharmacy regulation
Ozempic off-label (Canada)	$300-$350	Available but ethically discouraged	Health Canada approved for diabetes
Ozempic off-label (U.S.)	$900-$1,000	Available but ethically discouraged	FDA approved for diabetes

The U.S. retail price for Wegovy is 3.5 to 4 times higher than the Canadian retail price. This price differential has driven significant interest in Canadian pharmacy imports among U.S. residents, though legal barriers prevent most cross-border purchases (see section below).

Compounded semaglutide in Canada costs roughly 15-25% less than brand-name Wegovy. Canadian compounding pharmacies source semaglutide base powder from licensed suppliers and prepare it as a sterile injectable solution according to individual prescriptions. The quality and sterility standards are set by provincial pharmacy regulators and the National Association of Pharmacy Regulatory Authorities (NAPRA).

The cost advantage of compounded semaglutide comes from:

• No brand markup
• No marketing costs
• Prepared in smaller batches on demand
• Simpler packaging (multi-dose vials vs single-dose pens)

The trade-off is convenience. Compounded semaglutide requires manual drawing from a vial with a syringe, while Wegovy pens are pre-filled single-use injectors. For patients comfortable with manual injection, compounded options offer comparable efficacy at lower cost (Fitch et al., Obesity, 2024).

What most articles get wrong about Canadian pharmacy imports

Most U.S.-focused articles on Canadian Wegovy pricing imply or state outright that U.S. residents can order Wegovy from Canadian online pharmacies and have it shipped across the border. This is incorrect on multiple levels.

The legal reality:

1. FDA import rules. The FDA prohibits individuals from importing prescription medications from foreign countries, with narrow exceptions for personal use of medications unavailable in the U.S. Wegovy is FDA-approved and commercially available in the U.S., so it does not qualify for the personal importation exception (FDA, 2023).

1. Health Canada export rules. Health Canada prohibits Canadian pharmacies from exporting prescription medications that are in shortage or limited supply in Canada. While Wegovy is no longer on the official shortage list as of October 2024, Health Canada continues to discourage bulk exports to protect domestic supply (Health Canada, 2024).

1. Customs enforcement. U.S. Customs and Border Protection has authority to seize prescription medications at the border if they do not meet FDA import criteria. Seizure rates for GLP-1 medications increased 340% between 2022 and 2024 as cross-border demand surged (CBP, 2025).

1. Pharmacy licensing. Legitimate Canadian pharmacies require a valid Canadian prescription from a licensed Canadian prescriber. U.S. prescriptions are not valid in Canada. Websites claiming to fill U.S. prescriptions through "Canadian partner pharmacies" are typically operating in regulatory gray zones or are outright fraudulent.

The exception that proves the rule: some U.S. states have established formal programs to facilitate Canadian drug imports under specific conditions. Florida's Canadian Prescription Drug Importation Program, approved by the FDA in January 2024, allows the state to import certain medications in bulk for distribution through Florida pharmacies. Wegovy is not included in the approved medication list (Florida Agency for Health Care Administration, 2024).

The practical reality for U.S. residents:

If you are a U.S. resident seeking lower-cost semaglutide, the legally accessible options are:

• Compounded semaglutide from a U.S.-based compounding pharmacy (widely available, $199 to $399/month)
• Patient assistance programs from Novo Nordisk (income-restricted)
• Enrollment in clinical trials (limited availability)

Attempting to import Wegovy from Canada carries risk of product seizure, potential customs penalties, and no recourse if the product is counterfeit or degraded during shipping.

The three pathways Canadians actually use to access Wegovy

Based on prescription data patterns and patient surveys, Canadian patients access Wegovy through three primary pathways:

Pathway 1: Private insurance with prior authorization (approximately 35% of users).

This pathway works for patients with employer-sponsored or individually purchased private insurance that includes obesity medication coverage. The process:

1. Consultation with family physician or specialist
2. Documentation of BMI and comorbidities
3. Documentation of 3 to 6 months of lifestyle modification attempts
4. Physician submits prior authorization request to insurer
5. Approval typically takes 5 to 10 business days
6. Patient pays copay (usually 20-30%) at pharmacy
7. Annual reauthorization required

Success factors: thorough documentation, meeting BMI thresholds, having documented comorbidities (hypertension, dyslipidemia, prediabetes), and persistence through the appeal process if initially denied.

Pathway 2: Out-of-pocket payment (approximately 45% of users).

This pathway is straightforward but expensive. Patients pay full retail price (CAD $400 to $500/month) at the pharmacy. No prior authorization required, just a valid prescription from a Canadian prescriber.

Most patients on this pathway:

• Have tried and failed to get insurance coverage
• Have no private insurance
• Earn too much to qualify for patient assistance but not enough to afford it comfortably
• View it as a time-limited intervention (6 to 12 months) rather than indefinite treatment

The financial sustainability question is real. At CAD $5,400 per year, Wegovy represents 8-12% of median after-tax household income for middle-income Canadians. Most patients on the out-of-pocket pathway either transition to a maintenance strategy (lower dose, less frequent injections) after initial weight loss or switch to compounded alternatives.

Pathway 3: Compounded semaglutide (approximately 20% of users).

Compounded semaglutide has become the most common alternative to brand-name Wegovy in Canada. Provincial pharmacy regulations allow compounding pharmacies to prepare semaglutide for injection when prescribed by a licensed provider.

The compounded pathway:

1. Consultation with a provider who prescribes compounded semaglutide
2. Prescription sent to a compounding pharmacy
3. Pharmacy prepares semaglutide in multi-dose vials
4. Patient receives vial, syringes, and injection instructions
5. Patient draws and injects weekly doses manually
6. Refills as needed, typically monthly

Cost: CAD $250 to $350 per month, roughly 30-40% less than Wegovy.

Quality considerations: compounded medications are not subject to the same manufacturing oversight as Health Canada-approved drugs. Quality depends on the individual pharmacy's standards. Patients should verify that the compounding pharmacy is licensed by the provincial regulatory body and follows NAPRA sterile compounding standards.

The compounded route has grown rapidly since 2022. A 2025 survey by the Canadian Pharmacists Association found that compounded semaglutide prescriptions increased 420% between 2022 and 2024, driven primarily by Wegovy supply shortages and cost concerns (CPhA, 2025).

When private insurance denies coverage: the appeal process

Prior authorization denial is common. Approximately 30-35% of initial Wegovy prior authorization requests are denied by private insurers. The most common denial reasons:

1. Insufficient documentation of lifestyle modification. Insurer states that the patient has not adequately attempted diet and exercise before requesting medication.

1. BMI does not meet threshold. Patient has BMI between 27 and 30 but the documented comorbidity does not meet the plan's definition of obesity-related.

1. Medication not on formulary. The specific insurance plan excludes all obesity medications, even if the parent company covers them on other plans.

1. Experimental or investigational. Some older plans still classify obesity medications this way despite Health Canada approval and widespread clinical use.

The appeal process varies by insurer but generally follows this structure:

Step 1: Request detailed denial letter. Ask the insurer for a written explanation citing the specific policy language or clinical criteria that led to denial. This is your starting point for appeal.

Step 2: Gather additional documentation. Common gaps in initial submissions:

• Detailed diet and exercise log covering at least 12 weeks
• Documentation of supervised weight loss attempts (dietitian visits, weight management program enrollment)
• Lab work showing obesity-related metabolic abnormalities (elevated HbA1c, lipid panel, liver enzymes)
• Sleep study confirming obstructive sleep apnea
• Imaging or clinical notes documenting osteoarthritis or other mechanical complications of obesity

Step 3: Physician letter of medical necessity. A detailed letter from the prescribing physician addressing the specific denial reason and explaining why Wegovy is medically necessary for this patient. Effective letters cite clinical guidelines (Obesity Canada, Canadian Cardiovascular Society) and patient-specific factors that make lifestyle modification alone insufficient.

Step 4: Submit formal appeal. Most insurers have a two-tier appeal process: internal review, then external review. Internal review typically takes 15 to 30 days. External review (if internal appeal is denied) can take 45 to 60 days and involves an independent medical reviewer.

Step 5: Escalate if needed. If both appeal tiers fail, options include:

• Filing a complaint with the provincial insurance regulator
• Requesting employer HR department intervention (for employer-sponsored plans)
• Consulting a patient advocacy organization like Obesity Canada for template letters and guidance

Appeal success rates vary by denial reason. Appeals based on insufficient documentation succeed about 40% of the time when additional evidence is provided. Appeals challenging formulary exclusions succeed less than 10% of the time, as these are plan design decisions rather than clinical determinations (Conference Board of Canada, 2025).

The time investment is significant. Patients report spending 8 to 15 hours on average navigating the appeal process, including gathering records, coordinating with their physician's office, and following up with the insurer.

Cross-border access rules for U.S. residents

U.S. residents frequently ask whether they can access Canadian Wegovy pricing. The short answer: not legally through mail-order or personal importation.

What is not allowed:

• Ordering Wegovy from a Canadian online pharmacy and having it shipped to a U.S. address
• Traveling to Canada, filling a prescription at a Canadian pharmacy, and bringing it back across the border
• Using a prescription from a U.S. provider to fill medication at a Canadian pharmacy
• Importing Wegovy in quantities larger than a 90-day personal supply (and even 90-day supply does not meet FDA personal importation criteria for Wegovy)

What is theoretically allowed but practically difficult:

• Establishing residency in Canada, obtaining provincial health coverage, seeing a Canadian physician, and filling prescriptions as a Canadian resident (requires work permit or permanent residency, which takes months to years)

What the data shows people actually do:

A 2024 survey of U.S. patients seeking cross-border GLP-1 access found (Kesselheim et al., JAMA Health Forum, 2024):

• 23% attempted to order from a Canadian online pharmacy (87% of orders were either seized at customs, never delivered, or delivered a product that was clearly counterfeit)
• 12% traveled to a border city and attempted to fill a prescription (91% were turned away because they lacked a valid Canadian prescription)
• 8% used a "facilitator" service claiming to connect them with Canadian prescribers (62% received no product, 31% received a product of uncertain origin, 7% received what appeared to be legitimate medication)

The risk-benefit calculus is unfavorable. Even if a U.S. resident successfully receives Wegovy from a Canadian source, they have no way to verify the product's authenticity, sterility, or storage conditions during shipping. Counterfeit semaglutide has been identified in the North American supply chain, with at least 15 confirmed cases of counterfeit Ozempic and Wegovy seized by authorities between 2023 and 2025 (FDA, 2025).

The safer alternative for U.S. residents:

Compounded semaglutide from U.S.-based compounding pharmacies is legal, widely available, and costs $199 to $399 per month. While compounded medications are not FDA-approved, they are prepared by state-licensed pharmacies under state board of pharmacy oversight. Quality varies, but the regulatory framework exists and is enforceable.

Platforms like FormBlends connect U.S. patients with licensed U.S. providers who can prescribe compounded semaglutide, which is then prepared by U.S.-based compounding pharmacies and shipped domestically. This pathway avoids all cross-border legal issues and provides a traceable, regulated supply chain.

The decision tree: should you wait for coverage or pay out of pocket?

The decision to start Wegovy out-of-pocket vs waiting for insurance coverage or policy changes depends on individual financial and clinical factors. Here's the structured decision framework:

Decision point 1: Do you have private insurance that might cover Wegovy?

• Yes → Proceed to decision point 2
• No → Proceed to decision point 3

Decision point 2: Have you submitted a prior authorization request?

• No → Submit prior authorization with thorough documentation before considering out-of-pocket payment
• Yes, approved → Start treatment through insurance
• Yes, denied → Have you appealed with additional documentation?
• No → Appeal before paying out-of-pocket
• Yes, appeal denied → Proceed to decision point 3

Decision point 3: Can you sustain CAD $400-500/month for at least 6-12 months?

• No → Consider compounded semaglutide (CAD $250-350/month) or delay treatment until financial situation changes
• Yes → Proceed to decision point 4

Decision point 4: Do you have obesity-related comorbidities (hypertension, prediabetes, dyslipidemia, sleep apnea, cardiovascular disease)?

• Yes → Clinical urgency supports starting treatment now rather than waiting for policy changes
• No → Consider whether waiting 12-24 months for potential provincial coverage expansion is reasonable

Decision point 5: Are you comfortable with manual injection from a vial?

• Yes → Compounded semaglutide offers 30-40% cost savings with comparable efficacy
• No → Brand-name Wegovy pens are more convenient but more expensive

Decision point 6: What is your weight loss goal and timeline?

• 10-15% body weight loss over 6-12 months, then maintenance → Time-limited out-of-pocket treatment may be financially sustainable
• Indefinite treatment → Financial sustainability becomes critical; explore all coverage options and consider compounded alternatives

The clinical evidence supports earlier treatment for patients with obesity-related comorbidities. A 2024 analysis found that each year of delay in starting GLP-1 therapy for patients with obesity and prediabetes was associated with a 12% increased risk of progression to Type 2 diabetes (Wilding et al., Lancet Diabetes & Endocrinology, 2024). For these patients, paying out-of-pocket for 6 to 12 months while pursuing insurance appeals may be clinically justified.

For patients without urgent comorbidities, the calculus shifts. Waiting for potential provincial coverage expansion or further price reductions may be reasonable, particularly if the out-of-pocket cost represents a significant portion of discretionary income.

FAQ

How much does Wegovy cost in Canada without insurance? Wegovy costs CAD $400 to $500 per month at Canadian retail pharmacies without insurance. This is approximately USD $295 to $370 at April 2026 exchange rates. The price includes four weekly doses (one month of treatment).

Does Canadian health insurance cover Wegovy? No provincial health plan covers Wegovy for weight loss. Private insurance coverage varies; approximately 34% of employer-sponsored plans cover it with prior authorization and a 20-30% copay. Coverage requires BMI ≥30 or ≥27 with comorbidities and documentation of prior lifestyle modification attempts.

Can I buy Wegovy from Canada if I live in the United States? No. U.S. residents cannot legally import Wegovy from Canada. The FDA prohibits personal importation of medications that are already approved and available in the U.S. Canadian pharmacies require valid Canadian prescriptions from Canadian prescribers. Attempting to import carries risk of customs seizure and potential penalties.

Is Wegovy cheaper in Canada than the United States? Yes. Wegovy costs CAD $400-500/month in Canada vs USD $1,349-1,450/month in the United States, making the Canadian price roughly 75-80% lower. However, legal barriers prevent most U.S. residents from accessing Canadian pricing.

What is the cheapest way to get Wegovy in Canada? The cheapest legal option is compounded semaglutide from a licensed Canadian compounding pharmacy, which costs CAD $250-350/month. This requires a prescription from a Canadian provider. Brand-name Wegovy is cheapest at Costco Pharmacy (CAD $420-440/month) compared to other retail chains.

Does Wegovy require a prescription in Canada? Yes. Wegovy is a prescription-only medication in Canada. You need a valid prescription from a licensed Canadian physician, nurse practitioner, or other authorized prescriber. Online prescribing services exist but must connect you with a licensed Canadian provider.

How long does a box of Wegovy last? One box of Wegovy contains four single-dose pens, which provides four weekly injections (one month of treatment). Each pen is used once and then discarded. You cannot split doses or reuse pens.

Will Canadian provinces cover Wegovy in the future? Possibly. Saskatchewan announced in March 2026 that it will review GLP-1 obesity medication coverage in 2027. No other province has committed to a coverage review. Advocacy groups are pushing for coverage based on updated cost-effectiveness data showing cardiovascular benefits.

What is the difference between Wegovy and compounded semaglutide in Canada? Wegovy is the Health Canada-approved brand-name product made by Novo Nordisk, dispensed in pre-filled single-dose pens. Compounded semaglutide is prepared by licensed compounding pharmacies in multi-dose vials and requires manual drawing with a syringe. Both contain the same active ingredient (semaglutide). Compounded versions cost 30-40% less but require more user effort.

Can I get Wegovy covered if I have diabetes? Not under the Wegovy brand name. If you have Type 2 diabetes, your provider can prescribe Ozempic (semaglutide for diabetes), which is covered by most provincial health plans and private insurance with restrictions. Ozempic and Wegovy contain the same active ingredient but are approved for different indications.

How do I appeal a Wegovy insurance denial in Canada? Request a detailed written denial from your insurer, gather additional documentation (diet/exercise logs, comorbidity evidence, physician letter of medical necessity), and submit a formal appeal. Most insurers have two appeal tiers. Appeal success rate is approximately 40% when additional documentation addresses the specific denial reason.

Is Wegovy still in shortage in Canada? No. Health Canada removed Wegovy from the drug shortage database in October 2024. Supply is now stable in most urban areas. Some rural pharmacies report occasional 1-2 week delays for maintenance doses during high-demand periods, but widespread shortages have resolved.

Sources

1. Canadian Agency for Drugs and Technologies in Health (CADTH). Semaglutide for Chronic Weight Management: A Health Technology Assessment. CADTH. 2022.
2. Sharma AM, et al. Real-world cardiovascular outcomes with GLP-1 receptor agonists in obesity management: Canadian cohort analysis. Canadian Medical Association Journal. 2025.
3. Conference Board of Canada. Private Insurance Coverage of Obesity Medications in Canada: 2025 Survey Results. Conference Board of Canada. 2025.
4. Fitch A, et al. Comparative effectiveness of compounded vs brand-name semaglutide for weight management. Obesity. 2024.
5. U.S. Food and Drug Administration. Personal Importation Policy. FDA. 2023.
6. Health Canada. Guidance on Exportation of Drugs. Health Canada. 2024.
7. U.S. Customs and Border Protection. Pharmaceutical Seizure Statistics 2022-2024. CBP. 2025.
8. Florida Agency for Health Care Administration. Canadian Prescription Drug Importation Program: Approved Medication List. AHCA. 2024.
9. Canadian Pharmacists Association. Compounded Medication Trends in Canada 2022-2024. CPhA. 2025.
10. Kesselheim AS, et al. Cross-border pharmaceutical access patterns among U.S. patients seeking GLP-1 medications. JAMA Health Forum. 2024.
11. U.S. Food and Drug Administration. Counterfeit Semaglutide Products: Safety Alert. FDA. 2025.
12. Wilding JPH, et al. Timing of GLP-1 therapy initiation and diabetes prevention outcomes. Lancet Diabetes & Endocrinology. 2024.
13. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
14. Davies MJ, et al. Gastric emptying and satiety responses to GLP-1 receptor agonists. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Shoppers Drug Mart, Rexall, and Costco are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.